CHRONIC SPONTANEOUS URTICARIA
Clinical trials for CHRONIC SPONTANEOUS URTICARIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC SPONTANEOUS URTICARIA trials appear
Sign up with your email to follow new studies for CHRONIC SPONTANEOUS URTICARIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug trial for chronic hives withdrawn before starting
Disease control TerminatedThis study aimed to test if the drug ritlecitinib is safe and effective for treating chronic spontaneous urticaria (CSU), a condition causing long-lasting hives and itching. Eligible adults with CSU not well-controlled by standard antihistamines would have taken the oral drug dai…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE2 • Sponsor: Ahuva D Cices • Aim: Disease control
Last updated Apr 01, 2026 21:26 UTC
-
New pill tested to tame unpredictable chronic hives
Disease control OngoingThis is an early-stage study to test the safety and effects of a new oral drug called BGB-16673 in adults with chronic spontaneous urticaria (CSU), a condition causing unpredictable hives and itching. The study will involve about 34 participants who will receive either the drug o…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for uncontrollable hives? early drug trial underway
Disease control OngoingThis early-stage trial is testing a new drug called briquilimab for adults with chronic spontaneous urticaria (CSU), a condition causing long-lasting, itchy hives. The main goals are to find a safe dose and see if it helps reduce symptoms in people whose hives are not controlled …
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE1, PHASE2 • Sponsor: Jasper Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Extended hives treatment trial tests if benefits last
Disease control OngoingThis study follows adults with chronic spontaneous urticaria (CSU), also known as chronic hives, who previously took remibrutinib in earlier trials. It aims to collect long-term safety data and see if the treatment continues to control symptoms when some participants temporarily …
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug trial offers hope for people with uncontrollable hives
Disease control OngoingThis study is testing whether a new drug called barzolvolimab can safely reduce hives and itching in adults with chronic spontaneous urticaria (CSU) whose symptoms are not controlled by standard allergy medicines. About 976 participants will receive either the study drug or a pla…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New drug trial offers hope for stubborn, itchy hives
Disease control OngoingThis study is testing an investigational drug called barzolvolimab for adults with chronic spontaneous urticaria, a condition causing long-lasting, itchy hives. It is for people whose hives are not well-controlled even with standard antihistamine medications. The main goal is to …
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New pill challenges shot in fight against uncontrollable hives
Disease control OngoingThis study is testing if a new pill called remibrutinib can better control chronic hives in adults when standard allergy medicines don't work. It will compare the pill to a currently approved injection treatment (omalizumab) over one year, with an option for a second year on the …
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
First human test for new hives drug begins
Knowledge-focused OngoingThis is a very early, first-in-human study to check the safety and basic effects of a single dose of a new drug called LP-003. It involves 12 healthy adults and will measure how their bodies react to and process the drug. The goal is to gather initial safety data to see if LP-003…
Matched conditions: CHRONIC SPONTANEOUS URTICARIA
Phase: PHASE1 • Sponsor: Longbio Pharma • Aim: Knowledge-focused
Last updated Mar 19, 2026 14:55 UTC